Truist Securities analyst Joon Lee lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $50.00 (from $90.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Intellia Therapeutics (NTLA) PT Lowered to $9 at Goldman SachsMarch 3, 2025 6:29 AM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLAMarch 2, 2025 2:16 PM ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLAMarch 1, 2025 2:16 PM Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLAMarch 1, 2025 7:57 AM Form S-8 Intellia Therapeutics, February 28, 2025 4:05 PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLAFebruary 28, 2025 1:09 PM Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to SellFebruary 28, 2025 7:03 AM Intellia Therapeutics (NTLA) PT Lowered to $37 at RBC CapitalFebruary 28, 2025 6:28 AM JPMorgan Downgrades Intellia Therapeutics (NTLA) to NeutralFebruary 28, 2025 2:12 AM Form 10-K Intellia Therapeutics, For: Dec 31February 27, 2025 4:04 PM Intellia Therapeutics (NTLA) PT Raised to $14 at CitiFebruary 27, 2025 3:04 PM Form 8-K Intellia Therapeutics, For: Feb 27February 27, 2025 7:45 AM Intellia Therapeutics (NTLA) Tops Q4 EPS by 7cFebruary 27, 2025 7:30 AM